期刊文献+

武汉市胰岛素带量采购情况分析 被引量:11

Analysis of procurement of insulin with target quantity in Wuhan
原文传递
导出
摘要 目的:为其他省份乃至国家生物制品的药品带量采购工作启到借鉴的作用。方法:从武汉市胰岛素基本情况分析、胰岛素带量采购议价细则、胰岛素谈判议价结果3个方面对武汉市胰岛素带量采购情况做了一个整体分析。结果:武汉市制定了《带量采购中选药品采购量分配办法》,明确了保持医院用药习惯、减少品种更替原则,签订854份合同,签订合同量为1703520支,按照合同量估算可降低费用680.5万元。结论:武汉市胰岛素带量采购的执行降低了糖尿病患者的药品费用支出,是一项惠民工程。 OBJECTIVE To provide references for the procurement of biological products with target quantity in other provinces and even nationwide.METHODS An overall analysis was conducted for the procurement of insulin with target quantity in Wuhan from three aspects:basic analysis of insulin brands,bargaining rules of insulin brands and negotiation results of insulin brands.RESULTS Wuhan Municipality has formulated the Allocation Method for Purchasing Quantity of Selected Drugs purchased with Quantity which stipulated the principles of maintaining hospital drug habits and reducing variety turnover.A total of 854 contracts were signed with a contracted quantity of 1703520 drugs and the cost could be reduced by 6.805 million yuan according to the estimated contracted quantity.CONCLUSION The implementation of insulin brand purchasing in Wuhan Municipality reduces the drug expenditure of diabetics and it is a project of benefiting general public.
作者 申玲玲 吴宪弢 张斌 刘毅俊 SHEN Ling-ling;WU Xian-tiao;ZHANG Bing;LIU Yi-jun(Department of Pharmacy,Affiliated Tongji Hospital,Tongji Medical College,Huazhong University of Science&Technology,Hubei Wuhan 430030,China;Wuhan Pharmaceutical Equipment Joint Procurement Office,Hubei Wuhan 430016,China;Party School of Wuhan Health Commission,Hubei Wuhan 430016,China)
出处 《中国医院药学杂志》 CAS 北大核心 2021年第4期404-406,共3页 Chinese Journal of Hospital Pharmacy
关键词 糖尿病 胰岛素 带量采购 diabetes mellitus insulin procurement with target quantity
  • 相关文献

参考文献4

二级参考文献26

  • 1European Medicines Agency : Guideline on similar biological medicinal products EMEA, 2005, [ < http: www. emea europa. eu/pdfs/human/ biosimilar/043704, eupf> ].
  • 2Expert Committee on Biological Standardization: Guidelines on evaluation of similar biotherapeutic products (SBPs). World Health Organization, Geneva, Oct, 2009.
  • 3Chellekens H, Aloors E. Clinical comparability and European biosimilar regulations. Nat Biotect, 2010,28:28-31.
  • 4Kuhlmann M, Covic A. The protein science of biosimilars. Nephrol Dial Transplant, 2006,21 ( Suppl 5 ) :v4-v8.
  • 5Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Annals of oncology. 2008,19:411-419.
  • 6Kuhmann M, Man'e M. Lassons learned fl'om biosimilar epoetins and insulins. Brit J Diab Vas, 2010,10:90.
  • 7Kramer I, Sauer J. The new world of biosimilars: what diabetologists need to know about biosimilar insulins. Brit J Dias Vas, 2010, 10: 163.
  • 8European Medicines Agency. Pre-authorisation evaluation of medicines for human use. Withdrawal assessment report for insulin human rapid Marvel. Document reference EMEA/CHMP 17778/2007.
  • 9Casadevall N, Nataf J, Viron B, et al. Pure red cell aplasia and antierythopoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med, 2002,346:469-475.
  • 10Schellekens H. The First biosimilar epoetin : But how similar is it? C1 n J Am Soc Nephrol, 2008,3 :|74-178.

共引文献93

同被引文献58

引证文献11

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部